MAPK‐pathway activity, Lrrk2 G2019S, and Parkinson's disease
Identifieur interne : 001019 ( Main/Exploration ); précédent : 001018; suivant : 001020MAPK‐pathway activity, Lrrk2 G2019S, and Parkinson's disease
Auteurs : Linda R. White [Norvège] ; Mathias Toft [Norvège] ; Sylvia N. Kvam [Norvège] ; Matthew J. Farrer [États-Unis] ; Jan O. Aasly [Norvège]Source :
- Journal of Neuroscience Research [ 0360-4012 ] ; 2007-05-01.
English descriptors
- KwdEn :
Abstract
The 6055G>A mutation in the leucine‐rich repeat kinase 2 (LRRK2) gene results in a G2019S substitution in the mixed‐lineage kinase domain of Lrrk2, causing autosomal dominant Parkinson's disease (PD). We hypothesized the mutation alters cellular mitogen‐activated protein kinase (MAPK) signalling cascades, and might be detectable in tissues other than in the brain. We therefore compared total levels and activation of the signalling proteins Src, HSP27, p38 MAPK, JNK, and ERK, in extracts of leukocytes isolated from patients with PD carrying the G2019S mutation, healthy mutation carriers, patients with idiopathic PD, and healthy controls. Phosphorylation of Src, HSP27, and JNK was reduced significantly in cell extracts from patients with G2019S‐associated PD compared to healthy controls. Similarly, phosphorylation was reduced significantly in Src and HSP27 in the group of healthy carriers of the mutation, as well as in patients with idiopathic PD. Significant reductions in total Src were also observed in these three groups compared to the controls. The results of this pilot project therefore indicate significant alterations in key signalling proteins in leukocytes from patients with PD, and were most pronounced in G2019S‐associated PD. Changes in MAPK‐signalling may thus be common to PD pathophysiology, regardless of aetiology. Such changes may also be shown in blood samples during the preclinical stage of LRRK2‐associated PD, which could be particularly important for the development of neuroprotective strategies to delay onset, or slow progression of PD. © 2007 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jnr.21240
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">MAPK‐pathway activity, Lrrk2 G2019S, and Parkinson's disease</title><author><name sortKey="White, Linda R" sort="White, Linda R" uniqKey="White L" first="Linda R." last="White">Linda R. White</name></author><author><name sortKey="Toft, Mathias" sort="Toft, Mathias" uniqKey="Toft M" first="Mathias" last="Toft">Mathias Toft</name></author><author><name sortKey="Kvam, Sylvia N" sort="Kvam, Sylvia N" uniqKey="Kvam S" first="Sylvia N." last="Kvam">Sylvia N. Kvam</name></author><author><name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name></author><author><name sortKey="Aasly, Jan O" sort="Aasly, Jan O" uniqKey="Aasly J" first="Jan O." last="Aasly">Jan O. Aasly</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:99BA7B48AF9B6C7AEC7537AB5C00EC3E370F06EF</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/jnr.21240</idno><idno type="url">https://api.istex.fr/document/99BA7B48AF9B6C7AEC7537AB5C00EC3E370F06EF/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001254</idno><idno type="wicri:Area/Main/Curation">001051</idno><idno type="wicri:Area/Main/Exploration">001019</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">MAPK‐pathway activity, Lrrk2 G2019S, and Parkinson's disease</title><author><name sortKey="White, Linda R" sort="White, Linda R" uniqKey="White L" first="Linda R." last="White">Linda R. White</name><affiliation wicri:level="3"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Neuroscience, Norwegian University of Science and Technology, Trondheim</wicri:regionArea><placeName><settlement type="city">Trondheim</settlement><region type="région" nuts="2">Trøndelag</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Neurology, University Hospital of Trondheim, Trondheim</wicri:regionArea><placeName><settlement type="city">Trondheim</settlement><region type="région" nuts="2">Trøndelag</region></placeName></affiliation></author><author><name sortKey="Toft, Mathias" sort="Toft, Mathias" uniqKey="Toft M" first="Mathias" last="Toft">Mathias Toft</name><affiliation wicri:level="3"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Neuroscience, Norwegian University of Science and Technology, Trondheim</wicri:regionArea><placeName><settlement type="city">Trondheim</settlement><region type="région" nuts="2">Trøndelag</region></placeName></affiliation></author><author><name sortKey="Kvam, Sylvia N" sort="Kvam, Sylvia N" uniqKey="Kvam S" first="Sylvia N." last="Kvam">Sylvia N. Kvam</name><affiliation wicri:level="3"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Neurology, University Hospital of Trondheim, Trondheim</wicri:regionArea><placeName><settlement type="city">Trondheim</settlement><region type="région" nuts="2">Trøndelag</region></placeName></affiliation></author><author><name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville</wicri:cityArea></affiliation></author><author><name sortKey="Aasly, Jan O" sort="Aasly, Jan O" uniqKey="Aasly J" first="Jan O." last="Aasly">Jan O. Aasly</name><affiliation wicri:level="3"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Neuroscience, Norwegian University of Science and Technology, Trondheim</wicri:regionArea><placeName><settlement type="city">Trondheim</settlement><region type="région" nuts="2">Trøndelag</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Neurology, University Hospital of Trondheim, Trondheim</wicri:regionArea><placeName><settlement type="city">Trondheim</settlement><region type="région" nuts="2">Trøndelag</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neuroscience Research</title><title level="j" type="abbrev">J. Neurosci. Res.</title><idno type="ISSN">0360-4012</idno><idno type="eISSN">1097-4547</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-05-01">2007-05-01</date><biblScope unit="volume">85</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1288">1288</biblScope><biblScope unit="page" to="1294">1294</biblScope></imprint><idno type="ISSN">0360-4012</idno></series><idno type="istex">99BA7B48AF9B6C7AEC7537AB5C00EC3E370F06EF</idno><idno type="DOI">10.1002/jnr.21240</idno><idno type="ArticleID">JNR21240</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0360-4012</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>HSP27</term><term>JNK</term><term>Parkinson, MAPK signalling</term><term>Src</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The 6055G>A mutation in the leucine‐rich repeat kinase 2 (LRRK2) gene results in a G2019S substitution in the mixed‐lineage kinase domain of Lrrk2, causing autosomal dominant Parkinson's disease (PD). We hypothesized the mutation alters cellular mitogen‐activated protein kinase (MAPK) signalling cascades, and might be detectable in tissues other than in the brain. We therefore compared total levels and activation of the signalling proteins Src, HSP27, p38 MAPK, JNK, and ERK, in extracts of leukocytes isolated from patients with PD carrying the G2019S mutation, healthy mutation carriers, patients with idiopathic PD, and healthy controls. Phosphorylation of Src, HSP27, and JNK was reduced significantly in cell extracts from patients with G2019S‐associated PD compared to healthy controls. Similarly, phosphorylation was reduced significantly in Src and HSP27 in the group of healthy carriers of the mutation, as well as in patients with idiopathic PD. Significant reductions in total Src were also observed in these three groups compared to the controls. The results of this pilot project therefore indicate significant alterations in key signalling proteins in leukocytes from patients with PD, and were most pronounced in G2019S‐associated PD. Changes in MAPK‐signalling may thus be common to PD pathophysiology, regardless of aetiology. Such changes may also be shown in blood samples during the preclinical stage of LRRK2‐associated PD, which could be particularly important for the development of neuroprotective strategies to delay onset, or slow progression of PD. © 2007 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Norvège</li><li>États-Unis</li></country><region><li>Floride</li><li>Trøndelag</li></region><settlement><li>Trondheim</li></settlement></list><tree><country name="Norvège"><region name="Trøndelag"><name sortKey="White, Linda R" sort="White, Linda R" uniqKey="White L" first="Linda R." last="White">Linda R. White</name></region><name sortKey="Aasly, Jan O" sort="Aasly, Jan O" uniqKey="Aasly J" first="Jan O." last="Aasly">Jan O. Aasly</name><name sortKey="Aasly, Jan O" sort="Aasly, Jan O" uniqKey="Aasly J" first="Jan O." last="Aasly">Jan O. Aasly</name><name sortKey="Kvam, Sylvia N" sort="Kvam, Sylvia N" uniqKey="Kvam S" first="Sylvia N." last="Kvam">Sylvia N. Kvam</name><name sortKey="Toft, Mathias" sort="Toft, Mathias" uniqKey="Toft M" first="Mathias" last="Toft">Mathias Toft</name><name sortKey="White, Linda R" sort="White, Linda R" uniqKey="White L" first="Linda R." last="White">Linda R. White</name></country><country name="États-Unis"><region name="Floride"><name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001019 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001019 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:99BA7B48AF9B6C7AEC7537AB5C00EC3E370F06EF
|texte= MAPK‐pathway activity, Lrrk2 G2019S, and Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |